Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

This randomized controlled trial aims to evaluate the efficacy and safety of Becotatug Vedotin (MRG003), an antibody-drug conjugate (ADC), combined with the PD-1 inhibitor Pucotenlimab as induction therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (NPC), compared to the standard gemcitabine and cisplatin (GP) regimen combined with Pucotenlimab, followed by concurrent chemoradiotherapy (CCRT) and adjuvant immunotherapy.

NCT Number	NCT07524413
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Enrollment	514 participants
Start Date	2026-04
Primary Completion	2030-04 (estimated)
Study Completion	2032-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-13